A Multicentre, Randomised, Double-blind (Sponsor-unblinded), Placebo-controlled, Repeat Dose Study to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Active Plaque-type Psoriasis
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs GSK 2982772 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 16 Jan 2018 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 23 May 2017 Planned number of patients changed from 30 to 54.